A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Part of paid clinical trials in Menlo Park, California.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT03069378
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Cutaneous Angiosarcoma
  • Epithelioid Sarcoma
  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Talimogene Laherparepvec (T-VEC) — DRUG
    Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
  • Pembrolizumab — DRUG
    Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.

Study Details

The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.

Key Dates

Start date
Mar 3, 2017
Status verified
Jul 2025
Primary completion
Jul 22, 2025
Completion
Mar 31, 2026

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu
    Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.

Primary Outcome Measure

Best Objective Response Rate [ Time Frame: 24 weeks ]

Locations (5)

FacilityCityStateZIPSite coordinators
Enable Medicine (Specimen Analysis Only)Menlo ParkCalifornia94025-
Stanford University Medical CenterStanfordCalifornia94305-5408-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew York10604-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
MD Anderson Cancer Center (Data Analysis Only)HoustonTexas77030-

Related coverage on Hipa.ai

Find similar trials in Menlo Park, CA

By research site
Enable Medicine (Specimen Analysis Only)· Menlo Park, CAStanford University Medical Center· Stanford, CAMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center· New York, NYMD Anderson Cancer Center (Data Analysis Only)· Houston, TX

Related Studies